1634

1600

BIOTECHNOLOGY SYSTEMS BRANCH



#15 CD

CRF Problem Report

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

RECEIVED
JAN 0 6 2003
TECH CENTER 1600/2900

Application Serial Number: 09/635,027C
Filing Date: 08/04/2000
Date Processed by STIC: 12/31/02

STIC Contact: **Mark Spencer, 703-308-4212**

Nature of Problem:

The CRF (was):

____ (circle one) Damaged or Unreadable (for Unreadable, see attached)
____ Blank (no files on CRF) (see attached)
____ Empty file (filename present, but no bytes in file) (see attached)
____ Virus-infected. Virus name: _____ The STIC will not process the CRF.
____ Not saved in ASCII text
____ Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should **only** be the Sequence Listing.
✓ Did not contain a Sequence Listing. (see attached sample) – Please see sample of proper sequence listing attached
____ Other:

PLEASE USE THE CHECKER VERSION 3.1 PROGRAM TO REDUCE ERRORS. SEE BELOW FOR ADDRESS:
http:/www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.
Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.
Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<**http://www.uspto.gov/ebc/efs/downloads/documents.htm**> , **EFS Submission User Manual** - ePAVE)
2. **U.S. Postal Service**: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. **Hand Carry directly to:**
   U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
   Or
   U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. **Federal Express, United Parcel Service , or other delivery service to:** U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

09/635,027

NF-kappa B sequence on step 63 of original application was obtained form HIV-1 (nt 349-374, nt 9434- 9458)as shown on pages 8 and 11 of the sequence listing.

09/635027C

K03455. Human immunodefic...[gi:1906382]

Related Sequences,

Protein, PubMed, Taxonomy

```
LOCUS       HIVHXB2CG    9719 bp ss-RNA             VRL       19-AUG-1999
DEFINITION  Human immunodeficiency virus type 1 (HXB2), complete genome;
            HIV1/HTLV-III/LAV reference genome.
ACCESSION   K03455 M38432
VERSION     K03455.1  GI:1906382
KEYWORDS    TAR protein; acquired immune deficiency syndrome; complete genome;
            env protein; gag protein; long terminal repeat (LTR); pol protein;
            polyprotein; proviral gene; reverse transcriptase; transactivator.
SOURCE      Human immunodeficiency virus type 1.
  ORGANISM  Human immunodeficiency virus type 1
            Viruses; Retroid viruses; Retroviridae; Lentivirus; Primate
            lentivirus group.
REFERENCE   1  (bases 493 to 674; 9577 to 9718)
  AUTHORS   Ratner,L., Haseltine,W., Patarca,R., Livak,K.J., Starcich,B.,
            Josephs,S.F., Doran,E.R., Rafalski,J.A., Whitehorn,E.A.,
            Baumeister,K., Ivanoff,L., Petteway,S.R. Jr., Pearson,M.L.,
            Lautenberger,J.A., Papas,T.S., Ghrayeb,J., Chang,N.T., Gallo,R.C.
            and Wong-Staal,F.
  TITLE     Complete nucleotide sequence of the AIDS virus, HTLV-III
  JOURNAL   Nature 313 (6000), 277-284 (1985)
  MEDLINE   85111123
   PUBMED   2578615
REFERENCE   2  (bases 1 to 653)
  AUTHORS   Starcich,B., Ratner,L., Josephs,S.F., Okamoto,T., Gallo,R.C. and
            Wong-Staal,F.
  TITLE     Characterization of long terminal repeat sequences of HTLV-III
  JOURNAL   Science 227 (4686), 538-540 (1985)
  MEDLINE   85090465
REFERENCE   3  (sites)
  AUTHORS   Allan,J.S., Coligan,J.E., Barin,F., McLane,M.F., Sodroski,J.G.,
            Rosen,C.A., Haseltine,W.A., Lee,T.H. and Essex,M.
  TITLE     Major glycoprotein antigens that induce antibodies in AIDS patients
            are encoded by HTLV-III
  JOURNAL   Science 228 (4703), 1091-1094 (1985)
  MEDLINE   85192537
REFERENCE   4  (sites)
  AUTHORS   Sodroski,J., Patarca,R., Rosen,C., Wong-Staal,F. and Haseltine,W.
  TITLE     Location of the trans-activating region on the genome of human
            T-cell lymphotropic virus type III
  JOURNAL   Science 229 (4708), 74-77 (1985)
  MEDLINE   85244627
REFERENCE   5  (sites)
  AUTHORS   Arya,S.K., Guo,C., Josephs,S.F. and Wong-Staal,F.
  TITLE     Trans-activator gene of human T-lymphotropic virus type III
            (HTLV-III)
  JOURNAL   Science 229 (4708), 69-73 (1985)
```

<110> Smith, John; Smithgene Inc.

<120> Example of a Sequence Listing

<130> 01-00001

<140> PCT/EP98/00001
<141> 1998-12-31

<150> US 08/999,999
<151> 1997-10-15

<160> 4

<170> PatentIn version 2.0

<210> 1
<211> 389
<212> DNA
<213> Paramecium sp.

<220>
<221> CDS
<222> (279)...(389)

<300>
<301> Doe, Richard
<302> Isolation and Characterization of a Gene Encoding a Protease from Paramecium sp.
<303> Journal of Genes
<304> 1
<305> 4
<306> 1-7
<307> 1988-06-31
<308> 123456
<309> 1988-06-31

<400> 1

agctgtagtc attcctgtgt cctcttctct ctgggcttct caccctgcta atcagatctc 60

agggagagtg tcttgaccct cctctgcctt tgcagcttca caggcaggca ggcaggcagc 120

tgatgtggca attgctggca gtgccacagg cttttcagcc aggcttaggg tgggttccgc 180

cgcggcgcgg cggccccctc cgcgctcctc tcgcgcctct ctctcgctct cctctcgctc 240

Appendix 3, page 2

```
ggacctgatt  aggtgagcag  gaggaggggg  cagttagc      atg  gtt  tca  atg  ttc  agc   296
                                                  Met  Val  Ser  Met  Phe  Ser
                                                   1                   5

ttg  tct  ttc  aaa  tgg  cct  gga  ttt  tgt  ttg  ttt  gtt  tgt  ttg  ttc  caa   344
Leu  Ser  Phe  Lys  Trp  Pro  Gly  Phe  Cys  Leu  Phe  Val  Cys  Leu  Phe  Gln
                10                       15                  20

tgt  ccc  aaa  gtc  ctc  ccc  tgt  cac  tca  tca  ctg  cag  ccg  aat  ctt        389
Cys  Pro  Lys  Val  Leu  Pro  Cys  His  Ser  Ser  Leu  Gln  Pro  Asn  Leu
          25                       30                  35
```

<210> 2
<211> 37
<212> PRT
<213> Paramecium sp.

<400> 2

```
Met  Val  Ser  Met  Phe  Ser  Leu  Ser  Phe  Lys  Trp  Pro  Gly  Phe  Cys  Leu
 1               5                       10                  15

Phe  Val  Cys  Leu  Phe  Gln  Cys  Pro  Lys  Val  Leu  Pro  Cys  His  Ser  Ser
            20                       25                  30

Leu  Gln  Pro  Asn  Leu
          35
```

<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ.

<400> 3

```
Met  Val  Asn  Leu  Glu  Pro  Met  His  Thr  Glu  Ile
 1               5                       10
```

<210> 4
<400> 4
000

[Annex VIII follows]

identifiers and the accompanying information as set forth in the following table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials	M
<120>	Title of Invention		M
<130>	File Reference	Personal file reference	M, when filed prior to assignment of appl. number
<140>	Current Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOs	Count includes total number of SEQ ID NOs	M
<170>	Software	Name of software used to create the Sequence Listing	O
<210>	SEQ ID NO:#	Response shall be an integer representing the SEQ ID NO shown	M
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	M

<212>	Type	Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/RNA molecule shall be further described in the <220> to <223> feature section.	M
<213>	Organism	Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.	M
<220>	Feature	Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<221>	Name/Key	Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence
<222>	Location	Specify location within sequence; where appropriate state number of first and last bases/amino acids	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

		in feature	base was used in a sequence
<223>	Other Information	Other relevant information; four lines maximum	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA
<300>	Publication Information	Leave blank after <300>	O
<301>	Authors	Preferably max of ten named authors of publication; specify one name per line; preferable format: Surname, Other Names and/or Initials	O
<302>	Title		O
<303>	Journal		O
<304>	Volume		O
<305>	Issue		O
<306>	Pages		O
<307>	Date	Journal date on which data published; specify as yyyy-mm-dd, MMM-yyyy or Season-yyyy	O
<308>	Database Accession Number	Accession number assigned by database including database name	O
<309>	Database Entry Date	Date of entry in database; specify as yyyy-mm-dd or MMM-yyyy	O
<310>	Patent Document Number	Document number; for patent-type citations only. Specify as, for example, US 07/999,999	O

<311>	Patent Filing Date	Document filing date, for patent-type citations only; specify as yyyy-mm-dd	O
<312>	Publication Date	Document publication date, for patent-type citations only; specify as yyyy-mm-dd	O
<313>	Relevant Residues	FROM (position) TO (position)	O
<400>	Sequence	SEQ ID NO should follow the numeric identifier and should appear on the line preceding the actual sequence	M

5. Section 1.824 is revised to read as follows:

1.824 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.

(a) The computer readable form required by 1.821(c) shall meet the following specifications:

(1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.

(2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.

(3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.

(4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.

(5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.

(6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.

(b) Computer readable form submissions must meet these format requirements:

(1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;

(2) Operating System: MS-DOS, Unix or Macintosh;